



Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET

1

OR

2

Complet if Known

09/773.866

February 01, 2001

D. THOMAS, ET AL

1632

NOT

~~NOT YET ASSIGNED~~

1644

U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Documents		U.S. Patent Document Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Number	Kind Code (if known)			
RG	5,225,539	B1	WINTER	07-06-1993	RECEIVED
1	5,534,254	B1	HUSTON, et al.	07-09-1996	
1	5,723,322	B1	GUETTLER, et al.	03-03-1998	JUN 27 2001
1	5,801,227	B1	FANSLOW, III et al.	09-01-1998	
MR	5,674,492	B1	ARMITAGE et al.	10-07-1997	TECH CENTER 1600/2900
MR	4,946,778	B1	LADNER et al.	08-07-1990	

FOREIGN DOCUMENTS

Examiner
Signature

PHILLIP GAMBLER 8/20/01

Date
Considered

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



JUN 22 2001

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET

2

OF

2

Complete if Known

Application Number	09/773,866
Filing Date	FEBRUARY 01, 2001
First Named Inventor	D. THOMAS, ET AL
Group Art Unit	1632
Examiner Name	NOT YET ASSIGNED
Attorney Docket Number	1644 TNX00-03

RECEIVED

JUN 27 2001

TECH CENTER 1600, 2001

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s).	T 2
PG	C1	GUERDER et al., "A fail-safe mechanism for maintaining self-tolerance", <i>J. Exp. Med.</i> 176(2):553-564 (1992).	
	C2	BENNETT, S.R.M., et al., "Help for Cytotoxic T-Cell Responses is Mediated By CD40 Signaling", <i>Nature</i> 393:478-480 (1998).	
	C3	SCHOENBERGER, S.P. et al., "T-Cell Help for Cytotoxic T-Lymphocytes is Mediated by CD40-CD40L Interactions", <i>Nature</i> 393:480-483 (1998)	
	C4	ARMITAGE, R.J., "Tumor necrosis factor receptor superfamily members and their ligands", <i>Curr. Opin. Immunol.</i> 6(3):407-13 (1994).	
	C5	ALDERSON, et al., "CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40", <i>J. Exp. Med.</i> 178(2):669-674 (1993)	
	C6	CAUX, et al., "B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells", <i>J Exp Med.</i> 180(5):1841-1847 (1994).	
	C7	RIECHMANN, L., et al., "Reshaping Human Antibodies for Therapy", <i>Nature</i> 332: 323-327(1988).	
	C8	EVANS, M. J., et al., "Rapid Expression of an Anti-Human C5 Chimeric Fab Utilizing a Vector That Replicates in COS and 293 Cells", <i>J. Immunol. Meth.</i> 184: 123-138 (1995).	
	C9	TANG, A. et al., "Suppression of Murine Allergic Contact Dermatitis by CTLA41g: Tolerance Induction of Th2 Responses Requires Additional Blockade of CD-40 Ligand", <i>J. Immunol.</i> 157:117-125 (1996).	
	C10	RIDGE, J. P. et al., "A Conditioned Dendritic Cell Can Be a Temporal Bridge Between a CD4+ T-Helper and a T-Killer Cell", <i>Nature</i> 393:474-477 (1998).	
PG	C11	CAUX, C. et al., "Activation of human dendritic cells through CD40 cross-linking" <i>J Exp Med.</i> 180(4):1263-1272 (1994).	
Examiner Signature	PHILLIP GAMBEL	8/29/01	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.